secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001104659-25-047568
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Cellectar Biosciences Q1 2025 Net Loss Narrowed to $6.6M; Seeks EMA Conditional Approval for Iopofosine
--------------------------------------------------------------------------------

- Net loss for Q1 2025 was $6.6 million ($0.14 per share), compared to $26.6 million ($0.91 per share) in Q1 2024.
- Company seeking conditional EMA approval for iopofosine I 131 in Waldenstrom macroglobulinemia based on CLOVER WaM Phase 2 data with 59% major response rate in BTKi-treated patients.
- Cash and cash equivalents totaled $13.9 million as of March 31, 2025, expected to fund operations into Q4 2025.
- Board engaged Oppenheimer & Co. as exclusive financial advisor to explore strategic alternatives including mergers, acquisitions, or partnerships.
- Planned Phase 3 study for iopofosine I 131 would be a comparator randomized controlled study with 100 patients per arm, dependent on funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465925047568/0001104659-25-047568-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465925047568/tm2514904d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-047568

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer